Genmab Sustainability Profile
Genmab A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to developing differentiated antibody therapeutics. Founded in 1999, Genmab has made significant strides in the biopharmaceutical industry, focusing primarily on oncology and immunology. With a robust pipeline of proprietary and partnered products, Genmab's core offerings include monoclonal antibodies that target various cancers, distinguished by their unique mechanisms of action. The company has achieved notable milestones, including the successful development of its flagship product, Darzalex, which has transformed treatment paradigms for multiple myeloma. Positioned as a key player in the global biotechnology landscape, Genmab continues to expand its influence through strategic collaborations and a commitment to scientific excellence, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Genmab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genmab's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genmab's reported carbon emissions
In 2024, Genmab reported total carbon emissions of approximately 189,673,000 kg CO2e. This figure includes 534,000 kg CO2e from Scope 1 emissions, 1,163,000 kg CO2e from market-based Scope 2 emissions, and a significant 187,976,000 kg CO2e from Scope 3 emissions. The latter category encompasses various activities, with purchased goods and services contributing about 164,449,000 kg CO2e, followed by business travel at approximately 10,559,000 kg CO2e. In 2023, Genmab's total emissions were about 151,463,000 kg CO2e, with Scope 1 emissions at 317,000 kg CO2e and market-based Scope 2 emissions at 238,000 kg CO2e. The Scope 3 emissions for that year were approximately 150,908,000 kg CO2e, again primarily driven by purchased goods and services. Despite the substantial emissions figures, Genmab has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded any emissions data from a parent organization, and all reported figures are derived directly from Genmab A/S. Overall, Genmab's emissions profile highlights the significant impact of Scope 3 emissions, particularly from purchased goods and services, indicating potential areas for future reduction efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 341,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 298,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Genmab's Industry?
How Carbon Intensive is Genmab's Location?
Genmab's Scope 3 Categories Breakdown
Genmab's Scope 3 emissions, which increased by 25% last year and increased by approximately 28% since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 87% of Scope 3 emissions.
Top Scope 3 Categories
Genmab's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genmab has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
